ArticleExperimental hematology & oncology2018

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy.

Kalpna Desai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.